MedTrace Logo

Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe Atopic Dermatitis Clinical Trials

NCT04185584 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2021-03-17

No results posted yet for this study

Summary

This is a long-term safety follow-up study of the Phase I/II multicenter study of SCM-AGH in subjects with moderate to severe atopic dermatitis. subjects will be followed up for a maximum period of 240 weeks after the first dose of investigational product. Only subjects previously enrolled in protocol ADT2002 (ClinicalTrials.gov ID: NCT04179760) will be eligible for this long-term follow-up protocol.

Conditions

  • Dermatitis, Atopic

Interventions

OTHER

Not Applicable (Observational Study)

Not Applicable (Observational Study)

Sponsors & Collaborators

  • SCM Lifescience Co., LTD.

    lead INDUSTRY

Principal Investigators

  • Gwang Seong Choi, MD-Ph.D · Inha University Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-25
Primary Completion
2025-01-31
Completion
2025-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04185584 on ClinicalTrials.gov